アンチセンス療法・RNAi療法市場の2030年までの予測：投与経路別、適応症別、技術別、用途別、地域別の世界分析

Stratistics MRCによると、アンチセンス療法・RNAi療法の世界市場は2023年に16億6,000万米ドルを占め、予測期間中にCAGR 13.0％で成長し、2030年には39億米ドルに達すると予測されています。

アンチセンス療法は、一本鎖DNAオリゴヌクレオチドによる選択的かつ配列特異的な遺伝子発現阻害です。筋萎縮性側索硬化症やハンチントン病、アルツハイマー病の治療に用いられます。一方、RNA干渉（RNAi）療法は、二本鎖RNA（dsRNA）によって引き起こされ、dsRNAに応答して一本鎖標的RNAの配列特異的リボ核酸（mRNA）分解を引き起こします。RNAiは、ウイルス感染、神経変性疾患、特定のがんなど、幅広い疾患の治療に応用されています。

米国科学振興協会が2023年7月に発表した論文によると、UMass Chan医科大学とRUSH大学医療センターが開発したアンチセンス療法は、脆弱X症候群に罹患している人から採取した細胞標本において、FMRPというタンパク質の産生を回復させるのに有用であることが判明しました。

遺伝性疾患の増加

遺伝性疾患は個人のDNAの異常から生じるものであり、これらの疾患に対する従来の治療法はしばしば限定的でした。アンチセンス療法・RNAi療法は、これらの疾患の根本的な遺伝的原因を分子レベルで標的とすることにより、有望なアプローチを提供します。さらに、遺伝性疾患の有病率の増加により、アンチセンス療法・RNAi療法に焦点を当てた臨床試験や調査への取り組みが急増しています。臨床試験の成功や規制当局の承認は、これらの治療法の可能性をさらに実証し、市場の成長を後押ししています。

RNAiベース医薬品は高コスト

高度な技術と厳しい規制要件が絡む複雑な開発プロセスは、製造コストの上昇につながります。これらの費用はRNAi療法の価格設定に反映されることが多く、患者や医療システムにとってのアクセシビリティを制限しています。手ごろな価格という課題は普及を妨げ、市場の成長性を阻害する可能性があります。その結果、市場成長の妨げとなります。

新規ドラッグデリバリーの急速な普及とRNA療法の立ち上げ

高度なドラッグデリバリー技術の出現により、アンチセンス療法・RNAi療法の有効性と標的送達が強化され、その普及が促進されています。さらに、RNAベース医薬品が規制当局から承認され市場参入に成功したことで、投資家の信頼が高まり、研究開発への取り組みが活発化しました。このような技術の進歩と規制のマイルストーンの収束は、アンチセンス療法・RNAi療法市場を推進する好環境を作り出しています。

免疫反応

アンチセンス療法・RNAi療法に用いられるような外因性RNA分子が体内に導入されると、免疫系が活性化される可能性があります。これは、炎症性サイトカインの放出や免疫細胞の活性化を含む自然免疫反応を引き起こす可能性があります。また、身体の適応免疫系が外来RNAを脅威として認識し、治療分子に対する抗体の産生につながる可能性もあります。

COVID-19の影響

COVID-19の大流行は、アンチセンス療法・RNAi療法市場にさまざまな影響を与えました。一方では、mRNAワクチン開発に焦点が当てられたことで、RNAベースの技術受容が加速しました。しかし、臨床試験、サプライチェーン、研究活動に混乱が生じ、アンチセンス療法・RNAi療法の開発と商業化に遅れが生じています。RNA技術の認知度向上は好ましい結果であるが、業界は変化する情勢に適応するための課題に直面しており、ポストパンデミック時代における継続的成長のためには回復力と適応力が重要であることが強調されています。

予測期間中、RNAアンチセンスセグメントが最大になる見込み

RNAアンチセンスセグメントが最大のシェアを占めると推定されます。この革新的な治療アプローチは、疾患関連タンパク質の産生を阻害または変更することにより、遺伝子レベルで疾患を治療することを目的としています。RNAアンチセンス技術は、遺伝性疾患、がん、ウイルス感染の治療など、様々な応用が期待されています。遺伝子発現に正確に介入する能力を持つRNAアンチセンスは、広範な市場において極めて重要なセグメントであり、様々な病態に対する標的化・個別化治療ソリューションの開発に貢献しています。

予測期間中にCAGRが最も高くなると予想されるのはがんセグメント

がんセグメントは予測期間中に有利な成長を遂げると予測されます。アンチセンス療法・RNAi療法は、がんに関連する遺伝子を選択的に標的として発現を調節し、腫瘍の進行を抑制したりがん細胞死を促進したりするように設計されています。このセグメントには、個人の遺伝子プロファイルに合わせた個別化RNA治療など、多様なアプローチが含まれます。これらの治療法は標的を絞った精密なものであるため、特定の生物学的経路に取り組み、副作用を最小限に抑えながら治療効果を向上させることで、腫瘍学を変える可能性を秘めています。

最大のシェアを占める地域

アジア太平洋地域は、研究開発への投資の増加、慢性疾患の有病率の上昇、支持的な規制環境のため、予測期間中に最大の市場シェアを占めました。中国、日本、インドなどの主要諸国が最前線にあり、新規RNAベースの治療法の開発と商業化に注力しています。さらに、個別化医療に対する意識の高まりとともに、地元と世界のバイオテクノロジー企業間の共同研究が進歩を後押ししています。

CAGRが最も高い地域：

北米は、予測期間中に収益性の高い成長を遂げると予想されます。米国を筆頭に、この地域は製薬・バイオテクノロジー研究に多額の支出を行っており、これが新規RNAベース医薬品の研究開発を刺激しています。有利な規制状況、業界利害関係者間の戦略的提携、慢性疾患の高い有病率が市場拡大に寄与しています。また、北米には確立された医療インフラ、個別化医療への積極的なアプローチ、有力な市場プレーヤーが存在します。北米はアンチセンス療法・RNAi療法開発の最前線にあり、世界市場においてダイナミックかつ重要なプレーヤーとなっています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 技術分析
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のアンチセンス療法・RNAi療法市場：投与経路別

• 皮下
• 静脈
• 肺送達
• くも膜下
• 腹腔内注射
• その他

第6章 世界のアンチセンス療法・RNAi療法市場：適応症別

• 常染色体優性疾患
• 常染色体劣性疾患
• 染色体疾患
• その他

第7章 世界のアンチセンス療法・RNAi療法市場：技術別

• RNAアンチセンス
• RNA干渉

第8章 世界のアンチセンス療法・RNAi療法市場：用途別

• 眼疾患
• 呼吸器疾患
• 心臓代謝障害・腎臓障害
• がん
• 神経変性疾患
• 感染症
• 遺伝性疾患
• 皮膚疾患
• その他

第9章 世界のアンチセンス療法・RNAi療法市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Alnylam Pharmaceuticals, Inc.
• Ionis Pharmaceuticals（Akcea Therapeutics, Inc.）
• Biogen Inc.
• Sarepta Therapeutics, Inc.
• Arbutus Biopharma
• Silence Therapeutics
• Isarna Therapeutics GmbH
• Arrowhead Pharmaceuticals, Inc.
• Gene Signal International SA
• Benitec Biopharma Ltd
• Olix Pharmaceuticals
• GSK plc
• Sanofi
• Bio-Path Holdings Inc
• Antisense Therapeutics Limited.
• Quark Pharmaceuticals
• Merck
• Astellas Pharma Inc
• Marina Biosciences
• Dicerna Pharmaceuticals

List of Tables

• Table 1 Global Antisense & RNAi Therapeutics Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 3 Global Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
• Table 4 Global Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
• Table 5 Global Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
• Table 6 Global Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
• Table 7 Global Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
• Table 8 Global Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
• Table 9 Global Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
• Table 10 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
• Table 11 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
• Table 12 Global Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
• Table 13 Global Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 14 Global Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
• Table 15 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
• Table 16 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
• Table 17 Global Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
• Table 18 Global Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
• Table 19 Global Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 20 Global Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
• Table 21 Global Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
• Table 22 Global Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
• Table 23 Global Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
• Table 24 Global Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
• Table 25 Global Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
• Table 26 Global Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 27 North America Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 28 North America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 29 North America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
• Table 30 North America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
• Table 31 North America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
• Table 32 North America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
• Table 33 North America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
• Table 34 North America Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
• Table 35 North America Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
• Table 36 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
• Table 37 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
• Table 38 North America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
• Table 39 North America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 40 North America Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
• Table 41 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
• Table 42 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
• Table 43 North America Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
• Table 44 North America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
• Table 45 North America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 46 North America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
• Table 47 North America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
• Table 48 North America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
• Table 49 North America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
• Table 50 North America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
• Table 51 North America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
• Table 52 North America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 53 Europe Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 54 Europe Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 55 Europe Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
• Table 56 Europe Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
• Table 57 Europe Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
• Table 58 Europe Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
• Table 59 Europe Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
• Table 60 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
• Table 61 Europe Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
• Table 62 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
• Table 63 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
• Table 64 Europe Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
• Table 65 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 66 Europe Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
• Table 67 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
• Table 68 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
• Table 69 Europe Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
• Table 70 Europe Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
• Table 71 Europe Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 72 Europe Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
• Table 73 Europe Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
• Table 74 Europe Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
• Table 75 Europe Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
• Table 76 Europe Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
• Table 77 Europe Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
• Table 78 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 79 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 80 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 81 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
• Table 82 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
• Table 83 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
• Table 84 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
• Table 85 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
• Table 86 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
• Table 87 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
• Table 88 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
• Table 89 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
• Table 90 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
• Table 91 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 92 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
• Table 93 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
• Table 94 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
• Table 95 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
• Table 96 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
• Table 97 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 98 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
• Table 99 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
• Table 100 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
• Table 101 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
• Table 102 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
• Table 103 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
• Table 104 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 105 South America Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 106 South America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 107 South America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
• Table 108 South America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
• Table 109 South America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
• Table 110 South America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
• Table 111 South America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
• Table 112 South America Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
• Table 113 South America Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
• Table 114 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
• Table 115 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
• Table 116 South America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
• Table 117 South America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 118 South America Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
• Table 119 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
• Table 120 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
• Table 121 South America Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
• Table 122 South America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
• Table 123 South America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 124 South America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
• Table 125 South America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
• Table 126 South America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
• Table 127 South America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
• Table 128 South America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
• Table 129 South America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
• Table 130 South America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 131 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
• Table 132 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 133 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
• Table 134 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
• Table 135 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
• Table 136 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
• Table 137 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
• Table 138 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
• Table 139 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
• Table 140 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
• Table 141 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
• Table 142 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
• Table 143 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 144 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
• Table 145 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
• Table 146 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
• Table 147 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
• Table 148 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
• Table 149 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 150 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
• Table 151 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
• Table 152 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
• Table 153 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
• Table 154 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
• Table 155 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
• Table 156 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Antisense & RNAi Therapeutics Market is accounted for $1.66 billion in 2023 and is expected to reach $3.90 billion by 2030 growing at a CAGR of 13.0% during the forecast period. Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It is used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. RNAi has applications in treating a wide range of conditions, including viral infections, neurodegenerative diseases, and certain cancers.

According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome.

Market Dynamics:

Driver:

Rising incidence of genetic disorders

Genetic disorders result from abnormalities in an individual's DNA, and traditional treatment options for these conditions are often limited. Antisense and RNA interference (RNAi) therapies offer a promising approach by targeting the underlying genetic causes of these disorders at the molecular level. Furthermore, the increasing prevalence of genetic disorders has prompted a surge in clinical trials and research efforts focusing on antisense and RNAi therapies. Successful trials and regulatory approvals further validate the potential of these treatments, driving market growth.

Restraint:

High cost of RNAi based drugs

The complex development process, involving advanced technologies and stringent regulatory requirements, contributes to elevated production costs. These expenses are often reflected in the pricing of RNAi therapeutics, limiting accessibility for patients and healthcare systems. Affordability challenges can impede widespread adoption, hindering the market's growth potential. As a result, it will hamper market growth.

Opportunity:

Rapid adoption of novel drug delivery and launch of RNA therapeutics

The advent of advanced drug delivery technologies has enhanced the efficacy and targeted delivery of antisense and RNA interference (RNAi) therapeutics, fostering their widespread adoption. Furthermore, the regulatory approval and successful market entry of RNA-based treatments have bolstered investor confidence and fuelled research and development initiatives. This convergence of technological advancements and regulatory milestones has created a favourable environment, propelling the Antisense & RNAi Therapeutics Market.

Threat:

Immune responses

When exogenous RNA molecules, such as those used in antisense and RNA interference (RNAi) therapies, are introduced into the body, they may activate the immune system. This can trigger innate immune responses, including the release of pro-inflammatory cytokines and the activation of immune cells. Also, the body's adaptive immune system may recognize the foreign RNA as a threat, leading to the production of antibodies against the therapeutic molecules.

Covid-19 Impact

The COVID-19 pandemic has had a mixed impact on the antisense and RNAi therapeutics markets. On one hand, the focus on mRNA vaccine development has accelerated RNA-based technology acceptance. However, disruptions in clinical trials, supply chains, and research activities have caused delays in the development and commercialization of anti-sense and RNAi therapies. While increased recognition of RNA technologies is a positive outcome, the industry faces challenges in adapting to the changing landscape, emphasising the importance of resilience and adaptability for continued growth in a post-pandemic era.

The RNA antisense segment is expected to be the largest during the forecast period

The RNA antisense segment is estimated to hold the largest share. This innovative therapeutic approach aims to treat diseases at the genetic level by inhibiting or modifying the production of disease-related proteins. RNA antisense technology holds promise for various applications, including treating genetic disorders, cancers, and viral infections. With its ability to precisely intervene in gene expression, RNA antisense represents a pivotal segment within the broader market, contributing to the development of targeted and personalised therapeutic solutions for a range of medical conditions.

The cancer segment is expected to have the highest CAGR during the forecast period

The cancer segment is anticipated to have lucrative growth during the forecast period. Antisense and RNA interference (RNAi) therapies are designed to selectively target and modulate the expression of genes associated with cancer, inhibiting tumour progression or promoting cancer cell death. This segment encompasses a diverse range of approaches, including personalised RNA treatments tailored to individual genetic profiles. Because of their targeted and precise nature, these treatments have the potential to alter oncology by tackling certain biological pathways and improving therapeutic efficacy while minimising side effects.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to increased investment in research and development, the rising prevalence of chronic diseases, and a supportive regulatory environment. Key countries such as China, Japan, and India are at the forefront, with a focus on developing and commercialising novel RNA-based therapies. Furthermore, collaborations between local and global biotech firms, along with a growing awareness of personalised medicine, drive advancements.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The region, lead by the US, has made significant expenditures in pharmaceutical and biotechnology research, which has stimulated the development of novel RNA-based medicines. Favourable regulatory landscapes, strategic collaborations between industry stakeholders and a high prevalence of chronic diseases contribute to market expansion. It also has a well-established healthcare infrastructure, a proactive approach to personalised medicine, and prominent market players. North America is at the forefront of the development of antisense and RNAi treatments, making it a dynamic and significant player in the worldwide market.

Key players in the market

Some of the key players in the Antisense & RNAi Therapeutics Market include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Biogen Inc, Sarepta Therapeutics, Inc, Arbutus Biopharma, Silence Therapeutics, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc, Gene Signal International SA, Benitec Biopharma Ltd, Olix Pharmaceuticals, GSK plc, Sanofi, Bio-Path Holdings Inc, Antisense Therapeutics Limited., Quark Pharmaceuticals, Merck, Astellas Pharma Inc, Marina Biosciences and Dicerna Pharmaceuticals.

Key Developments:

In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche; to develop and market, zilebesiran, investigational ribonucleic acid interference (RNAi) therapeutic to treat hypertension

In March 2023, OliX Pharmaceuticals, Inc. dosed the first patient in a Phase 1 clinical trial of an investigational RNAi therapeutic designed to treat age-related macular degeneration (AMD)

Routes of Administration Covered:

• Subcutaneous Route
• Intravenous Route
• Pulmonary Delivery
• Intrathecal Route
• Intraperitoneal Injection
• Other Routes of Administration

Indications Covered:

• Autosomal Dominant Disease
• Autosomal Recessive Disease
• Chromosomal Disease
• Other Indications

Technologies Covered:

• RNA Antisense
• RNA Interference

Applications Covered:

• Ocular Disorders
• Respiratory Disorders
• Cardio metabolic & Renal Disorders
• Cancer
• Neurodegenerative Disorders
• Infectious Diseases
• Genetic Disorders
• Skin Diseases
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Antisense & RNAi Therapeutics Market, By Route of Administration

• 5.1 Introduction
• 5.2 Subcutaneous Route
• 5.3 Intravenous Route
• 5.4 Pulmonary Delivery
• 5.5 Intrathecal Route
• 5.6 Intraperitoneal Injection
• 5.7 Other Routes of Administration

6 Global Antisense & RNAi Therapeutics Market, By Indication

• 6.1 Introduction
• 6.2 Autosomal Dominant Disease
• 6.3 Autosomal Recessive Disease
• 6.4 Chromosomal Disease
• 6.5 Other Indications

7 Global Antisense & RNAi Therapeutics Market, By Technology

• 7.1 Introduction
• 7.2 RNA Antisense
• 7.3 RNA Interference

8 Global Antisense & RNAi Therapeutics Market, By Application

• 8.1 Introduction
• 8.2 Ocular Disorders
• 8.3 Respiratory Disorders
• 8.4 Cardio metabolic & Renal Disorders
• 8.5 Cancer
• 8.6 Neurodegenerative Disorders
• 8.7 Infectious Diseases
• 8.8 Genetic Disorders
• 8.9 Skin Diseases
• 8.10 Other Applications

9 Global Antisense & RNAi Therapeutics Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Alnylam Pharmaceuticals, Inc.
• 11.2 Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)
• 11.3 Biogen Inc.
• 11.4 Sarepta Therapeutics, Inc.
• 11.5 Arbutus Biopharma
• 11.6 Silence Therapeutics
• 11.7 Isarna Therapeutics GmbH
• 11.8 Arrowhead Pharmaceuticals, Inc.
• 11.9 Gene Signal International SA
• 11.10 Benitec Biopharma Ltd
• 11.11 Olix Pharmaceuticals
• 11.12 GSK plc
• 11.13 Sanofi
• 11.14 Bio-Path Holdings Inc
• 11.15 Antisense Therapeutics Limited.
• 11.16 Quark Pharmaceuticals
• 11.17 Merck
• 11.18 Astellas Pharma Inc
• 11.19 Marina Biosciences
• 11.20 Dicerna Pharmaceuticals